TMED — EGF Theramed Health Cashflow Statement
0.000.00%
Last trade - 00:00- CA$1.51m
- CA$1.60m
- 12
- 15
- 56
- 17
Annual cashflow statement for EGF Theramed Health, fiscal year end - June 30th, CAD millions except per share, conversion factor applied.
2020 June 30th | 2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -21.6 | -0.744 | -1.36 | -0.643 | -0.296 |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | 19.6 | -0.293 | 0.374 | 0.048 | 0.094 |
| Unusual Items | |||||
| Equity in Net Earnings/Losses | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.11 | 0.254 | -0.004 | 0.02 | 0.068 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Payable / Accrued Expenses | |||||
| Cash from Operating Activities | -1.71 | -0.784 | -0.993 | -0.576 | -0.135 |
| Capital Expenditures | -0.719 | 0 | — | — | — |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -0.175 | 0.41 | 0 | — | — |
| Acquisition of Business | |||||
| Sale of Business | |||||
| Sale/Maturity of Investment | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -0.894 | 0.41 | 0 | — | — |
| Financing Cash Flow Items | -0.023 | 0 | — | — | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 2.83 | 0.712 | 0.306 | 0.573 | 0.133 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 0.231 | 0.339 | -0.687 | -0.004 | -0.002 |